Science and Research

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >/=1% by the USA Food and Drug Administration

  • Mountzios, G.
  • Remon, J.
  • Novello, S.
  • Blais, N.
  • Califano, R.
  • Cufer, T.
  • Dingemans, A. M.
  • Liu, S. V.
  • Peled, N.
  • Pennell, N. A.
  • Reck, M.
  • Rolfo, C.
  • Tan, D.
  • Vansteenkiste, J.
  • West, H.
  • Besse, B.
Publication details
DOI: 10.1093/annonc/mdz295
Journal: Ann Oncol
Pages: 1686-1688 
Number: 11
Work Type: Other
Location: ARCN
Disease Area: LC
Partner / Member: Ghd
Access-Number: 31504132
See publication on PubMed

DZL Engagements

chevron-down